Boehringer Ingelheim has released data from its Phase I INVICTAN-1 trial involving BI 695502, the company’s bevacizumab biosimilar candidate, which shows that the drug is a bioequivalent of Avastin, which is licensed in the U.S. and E.U.
Avastin, which is an angiogenesis inhibitor, was developed for the treatment of multiple types of cancers.
“Findings from this study are an important step to confirm that BI 695502 is biosimilar to Avastin, and we look forward to the completion of the ongoing pivotal Phase III trial in lung cancer,” Boehringer Ingelheim Vice President Dr. Sandeep Athalye said. “These data show our commitment to develop high-quality therapeutic options for patients with cancer and contribute to the long-term sustainability of global health care systems.”
During the INVICTAN-1 trial, BI 695502 achieved all of its main and secondary goals. The data from the trial was presented at the American Association of Pharmaceutical Scientists Annual Meeting as a poster presentation.